NASDAQ NMS - GLOBAL MARKET · ENGN
-0.90% · -$0.0160 · Vol 242.7K
Market closed · last close 4:00 PM ET · price as of 17:56:24 ET
enGene Therapeutics Inc

enGene Therapeutics Inc

Biotechnology
$1.75
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
ENGN
enGene Therapeutics Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

65/ 100
Veridion Score
BUY BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ENGN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ENGN catalysts
About enGene Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2023
Employees
82
Country
CA

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.79
Day high
$1.80
Day low
$1.77
Previous close
$1.77
52W high
$12.17
-85.59% from high
52W low
$1.44
3% of range
Market cap
$119.2M
P/E
1.61×
EPS
$1.09
Beta
2.88
Shares out
67M
Volume
242.7K
0.34× rel vol
Avg volume
721.3K
VWAP
$1.78
Price history computed in-house
1W
+3.18%
1M
-3.63%
3M
-0.34%
1Y
-59.40%
YTD
-80.58%
SMA 50 $1.79 · below
SMA 200 $5.91 · below
52W position 3%

ENGN overview

Veridion Score
65
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ENGN.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ENGN Form 4 filings
Public disclosures

Congress activity in ENGN

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ENGN in the cached public ledger.

Federal contracts

ENGN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ENGN in this window.
Lobbying spend

ENGN lobbying filings, year to date.

Registered lobbying filings matched to enGene Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ENGN in this window.
Loading news for ENGN
Analyst ratings
Sovereign unlock shows live analyst consensus for ENGN.
Options
Sovereign unlock shows live options positioning for ENGN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.